As many receptor tyrosine kinases (RTKs) are overexpressed in mCRPC and predictive of poor prognosis [3], inhibitors of RTKs (Tyrosine kinase inhibitors, TKIs), such as c-MET (mesenchymal to epithelial transition, proto-oncogene), VEGFR2 (vascular endothelial growth factor receptor 2), FGFRs (Fibroblast growth factor receptors), PDGFR (platelet-derived growth factor receptors), HER2/neu (human epidermal growth factor receptor 2/neu), and IGF-1R (insulin-like growth factor 1 receptor) have undergone many clinical trials in PCa [3]. This evidence concerns the gene ERBB2 and posterior cortical atrophy.